| Document |
Document Title |
|
WO/2018/099946A1 |
The present invention relates to novel bicyclic nucleosides and oligomers prepared therefrom. In particular, the present invention relates to a compound of formula (I), wherein one of T1 and T2 is OR1 or OR2; and the other of T1 and T2 i...
|
|
WO/2018/101431A1 |
The purpose of the present invention is to provide a 2-O-α-D-glycosyl-L-ascorbic acid composition which has excellent moisturizing properties and excellent skin wettability. The present invention relates to: a 2-O-α-D-maltosyl-L-ascorb...
|
|
WO/2018/096831A1 |
Provided are a novel nucleoside derivative or salt thereof, polynucleotide synthesis reagent, polynucleotide production method, polynucleotide, and binding nucleic acid molecule production method. This nucleoside derivative or salt there...
|
|
WO/2018/092107A1 |
Novel anti-Viral and anti-Cancer molecule containing nucleobase or its derivatives or its analogues attached to an Ascorbic Acid molecule or its derivatives or its analogues with or without an oxygen bond in-between.
|
|
WO/2018/094148A1 |
Compounds that modulate the conversion of AMP to adenosine by 5'- nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions ...
|
|
WO/2018/091542A1 |
The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relat...
|
|
WO/2018/093717A1 |
The present invention features compositions and methods for the treatment of HCV infection. In one embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) Compound 2a o...
|
|
WO/2018/089830A1 |
The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X", Z 1, Z2, n, R 1, R2, R3, R4, R5, R6,,R7, and R 8 are described herein, reduced analogs thereof, modified derivativ...
|
|
WO/2018/085833A2 |
The disclosure is directed to compounds of Formula I, Formula II, and Formula III [Formulas should be inserted here]. Methods of their use and preparation are also described.
|
|
WO/2018/085307A1 |
The present invention provides prodrugs of clofarabine. The compounds of the invention have formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 is H or -C(=0)-X-R3 and R2 is H or -C(=0)-Y-R4, wherein X and Y are each i...
|
|
WO/2018/081785A1 |
An antiviral compound of the following formula (I) is provided or a salt or a pharmaceutically acceptable salt thereof, where B is a naturally occurring or non-naturally occurring base; R1 is a C2-C14 alkyl group; X is O, S, CH=CH (cis) ...
|
|
WO/2018/079503A1 |
Provided is a simple and practical method for removing iron ions, as a method for purifying P1,P4-di(uridine 5'-)tetraphosphate from a solution that contains iron ions. This method for purifying P1,P4-di(uridine 5'-)tetraphosphate by rem...
|
|
WO/2018/071531A1 |
The disclosure provides linked purine pterin compounds of Formula I that are novel inhibitors of HPPK, a kinase responsible for an essential step in the biosynthesis of folic acid. (Formula I) The variables, e.g., A1-A3, R1-R4, B1-B2, an...
|
|
WO/2018/070543A1 |
The purpose of the present invention is to provide a method for producing a phosphoramidite suitable for nucleic acid production (synthesis) with high efficiency and high purity. A phosphoramidite which allows for efficient nucleic acid ...
|
|
WO/2018/067241A1 |
The present invention relates to macroheterocyclic nucleoside derivatives and their analogues, production and use thereof. These compounds are the prodrugs for treating viral and cancerous diseases and are inhibitors of HCV NS5B polymera...
|
|
WO/2018/066690A1 |
The purpose of the present invention is to provide: crystals of cytidine diphosphate choline which contain no methanol and have improved powder properties; and a process for producing the crystals. The process according to the present in...
|
|
WO/2018/064078A1 |
Apparatus and means by which a polysaccharide or other heterogeneous polymer is concatenated with a nucleic acid polymer that is captured by a primer on a polymerase tethered to a bead trapped by a nanopore. The translocation of the nano...
|
|
WO/2018/059214A1 |
Provided are compounds affecting SAICAR synthesis, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain compounds...
|
|
WO/2018/060323A1 |
The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and R3 are defined as in claim 1, which have valuable pharmacological properties, particularly are modulators of STING.
|
|
WO/2018/051581A1 |
Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleo...
|
|
WO/2018/051903A1 |
[Problem] To provide a compound having excellent antibacterial properties and a compound having an excellent ability to enhance antibacterial properties of another antibacterial agent. [Solution] A sugar derivative having an antibacteria...
|
|
WO/2018/052063A1 |
Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleo...
|
|
WO/2018/051580A1 |
Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleo...
|
|
WO/2018/049535A1 |
Nucleoside analogues that can be used as anticancer or antiviral agents are presented. These compounds are nucleoside and/or nucleotide prodrugs. In particular, the subject matter relates to nucleoside analogues comprising a tetrahydrofu...
|
|
WO/2018/049534A1 |
Nucleoside and nucleotide analogues that can be used as cardioprotective agents are provided. The nucleosides and nucleotide analogues comprise tetrahydrofuranyl or tetrahydrothienyl moieties with quaternary stereogenic all-carbon center...
|
|
WO/2018/052064A1 |
Provided are a novel nucleoside derivative or a salt thereof, a reagent for synthesizing a polynucleotide, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. This nucleo...
|
|
WO/2018/045997A1 |
The present application falls within the field of drug synthesis, and relates to a method for preparing 2-fluoro-2-methyldeoxynucleoside as an intermediate of Sofosbuvir. In particular, the present application provides a method for prepa...
|
|
WO/2018/047715A1 |
The purpose of the present invention is to provide: crystals of β-nicotinamide mononucleotide (NMN) which have excellent storage stability; and a production process therefor. According to the present invention, crystals of NMN can be pr...
|
|
WO/2018/047909A1 |
Disclosed is a purine nucleoside derivative represented by formula (Ia) or the like. In the formula, each of X1 and X2 independently represents a nitrogen atom, -CH= or -CR2= (wherein R2 represents an alkyl group); Ar represents an optio...
|
|
WO/2018/048937A1 |
The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.
|
|
WO/2018/049145A1 |
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
|
|
WO/2018/045317A1 |
Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4'-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The phosphate analogs are bo...
|
|
WO/2018/042841A1 |
A SAMe-containing material having a high SAMe content can be obtained by a method which comprises: a heating/dissolving step for supplying water and brown sugar to a culture tank and dissolving the brown sugar by heating; a culture step ...
|
|
WO/2018/033639A1 |
The present invention is directed to lactones of the following structural formula for use as precursors of NAD, and their use as nutritional supplements.
|
|
WO/2018/033492A1 |
The invention proves an oligonucleotide comprising one or more carboxylated 2'- amino-LNA nucleotide units. The invention also provides a method of transfecting cells with the oligonucleotide, a method of treating a human or animal by th...
|
|
WO/2018/034987A1 |
Methods and compounds are disclosed for irreversibly inhibiting a DNA repair enzyme that possesses lyase activity.
|
|
WO/2018/033593A1 |
The present invention relates to novel compounds for the treatment of Hepatitis C.
|
|
WO/2018/033719A1 |
The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, s...
|
|
WO/2018/028494A1 |
A gemcitabine ProTide hypoxic-activated prodrug and a use thereof in the preparation of a medicament for treating tumors. The general structural formula thereof is formula (A), wherein: one of R1 and R2 is a hypoxic-activated group of -C...
|
|
WO/2018/031818A2 |
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Picornaviridae and/or Flaviviridae viral infections with one or more nucleotide analogs.
|
|
WO/2018/024265A1 |
Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides of general formula (I), where R is selected from the group comprising furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl or chloro...
|
|
WO/2018/023205A1 |
A purification method for nicotinamide mononucleotide, relating to a method for purifying an NMN crude product obtained via a biocatalysis method. The purpose of the present method is to solve the problems in existing NMN purification me...
|
|
WO/2018/019748A1 |
The invention relates to a compound of formula (I) wherein R2 and R4 are joined and together form a group, such a -CH2O-. The compound of formula (I) can be used in the manufacture of 5'S-LNA oligonucleotides as antisense drugs.
|
|
WO/2018/019188A1 |
Provided are a crystal form A of a nucleoside phosphoramidate prodrug as shown in formula I and a preparation method therefor. The crystal form A at least has an X-ray powder diffraction (XRPD) pattern with peaks at the 2θ angles of 6.9...
|
|
WO/2018/015821A1 |
The present invention relates to an improved, commercially viable and industrially advantageous process for the preparation of Sofosbuvir. The present invention involves use of reagents that are less expensive, easier to handle and eco-f...
|
|
WO/2018/014111A1 |
There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours po...
|
|
WO/2018/011094A1 |
The present invention relates to a compound of the general formula (1), wherein the pyranose ring is alpha-D-galactopyranose, A is selected from (2), and (3). The compound of formula (1) is suitable for use in a method for treating a dis...
|
|
WO/2018/010965A1 |
Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related m...
|
|
WO/2018/011093A1 |
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal...
|
|
WO/2018/013937A1 |
Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in ne...
|
